A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2)
暂无分享,去创建一个
Henry W. Long | P. Kantoff | M. Freedman | S. Fine | J. Armenia | T. Gerke | Xintao Qiu | M. Pomerantz | K. Komura | Subhiksha Nandakumar | Edward P. O’Connor | Connor Bell | Si’Ana A. Coggins | Nabeela Khan | G. Chakraborty | Baek Kim | G. Lee | Yuki Yoshikawa | Huiyong Zhao | Ying Z. Mazzu | HuiYong Zhao | M. Atiq | Si'Ana A Coggins
[1] A. Zoubeidi,et al. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition , 2017, Clinical Cancer Research.
[2] B. Geiger,et al. Dual role of E-cadherin in the regulation of invasive collective migration of mammary carcinoma cells , 2017, Scientific Reports.
[3] F. Saad,et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Qi,et al. ATR-CHK1-E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG. , 2016, Biochimica et biophysica acta.
[5] Hamid Bolouri,et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer , 2016 .
[6] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[7] André F. Vieira,et al. P-cadherin and the journey to cancer metastasis , 2015, Molecular Cancer.
[8] Henry W. Long,et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.
[9] Jesika S. Faridi,et al. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer , 2015, Molecular Cancer Therapeutics.
[10] Zhi-Hua Zhu,et al. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. , 2015, Biochemical and biophysical research communications.
[11] Yate-Ching Yuan,et al. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro , 2015, Molecular Pharmacology.
[12] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[13] C. Ponting,et al. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer , 2014, BMC Cancer.
[14] Peter Kraft,et al. Association of Prostate Cancer Risk Variants with Gene Expression in Normal and Tumor Tissue , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[15] R. Schinazi,et al. dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages , 2014, Retrovirology.
[16] Chris Sander,et al. Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.
[17] R. Weiss,et al. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies , 2014, Oncogene.
[18] Mariano J. Alvarez,et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. , 2014, Cancer cell.
[19] Soon-Ja Kim,et al. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer. , 2014, Urologic oncology.
[20] Yun Yen,et al. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers. , 2014, Urologic oncology.
[21] Yun Yen,et al. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. , 2013, Cancer research.
[22] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[23] Demin Li,et al. A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis , 2013, Cancer cell.
[24] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[25] Manuel A. S. Santos,et al. P‐cadherin functional role is dependent on E‐cadherin cellular context: a proof of concept using the breast cancer model , 2013, The Journal of pathology.
[26] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[27] Klemens Vierlinger,et al. Meta-Analysis of Gene Expression Signatures Defining the Epithelial to Mesenchymal Transition during Cancer Progression , 2012, PloS one.
[28] Jan Koster,et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification , 2012, Proceedings of the National Academy of Sciences.
[29] M. Pagano,et al. Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair , 2012, Cell.
[30] R. Gomis,et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. , 2012, The Journal of clinical investigation.
[31] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[32] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .
[33] G. Stein,et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2 , 2011, Proceedings of the National Academy of Sciences.
[34] T. Beißbarth,et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets , 2011, International journal of cancer.
[35] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[36] T. Kunkel,et al. Mechanisms of mutagenesis in vivo due to imbalanced dNTP pools , 2010, Nucleic acids research.
[37] Peter M Schlag,et al. Identification of early molecular markers for breast cancer , 2011, Molecular Cancer.
[38] T. Beißbarth,et al. Mutated KRAS results in overexpression of DUSP4, a MAP‐kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas , 2010, Genes, chromosomes & cancer.
[39] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[40] Jing Ma,et al. Immunohistochemical expression of BRCA1 and lethal prostate cancer. , 2010, Cancer research.
[41] Jing Chen,et al. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..
[42] Y. Yen,et al. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis , 2009, Molecular Cancer.
[43] R. Bronson,et al. Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. , 2008, Cancer research.
[44] Yan Liu,et al. Risk factors for prostate cancer incidence and progression in the health professionals follow‐up study , 2007, International journal of cancer.
[45] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[46] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[47] W. Gerald,et al. Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.
[48] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[49] C. Maccalman,et al. Cadherin switching in ovarian cancer progression , 2003, International journal of cancer.
[50] A. Chabes,et al. Controlled Protein Degradation Regulates Ribonucleotide Reductase Activity in Proliferating Mammalian Cells during the Normal Cell Cycle and in Response to DNA Damage and Replication Blocks* , 2000, The Journal of Biological Chemistry.
[51] Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.